Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
暂无分享,去创建一个
D B Evans | M. Ellis | Baljit Singh | L. Mauriac | F. Jänicke | W. Miller | D. Evans | A. Coop | M. Dugan | F Jänicke | C. Brady | M. Borgs | W R Miller | E. Quebe-Fehling | M Dugan | M J Ellis | A Coop | B Singh | L Mauriac | A Llombert-Cussac | C Brady | E Quebe-Fehling | M Borgs | D. Evans | B. Singh | A. Llombert-Cussac | E. Quebe‐Fehling | Antonio Llombert-Cussac | D. Evans
[1] A. Gown,et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[3] J. Cairns,et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. , 1992, British Journal of Cancer.
[4] R Akita,et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. , 1993, Cancer research.
[5] I. Ellis,et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. , 1995, British Journal of Cancer.
[6] M. Ellis,et al. Preoperative endocrine therapy for older women with breast cancer: renewed interest in an old idea. , 2000, Cancer control : journal of the Moffitt Cancer Center.
[7] J M Esteban,et al. Quantitative immunohistochemical assay for hormonal receptors: technical aspects and biological significance. , 1994, Journal of cellular biochemistry. Supplement.
[8] W. McGuire,et al. Progesterone receptors as a prognostic factor in stage II breast cancer. , 1983, The New England journal of medicine.
[9] A. Buzdar,et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Gelman,et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Boni,et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] G M Clark,et al. Steroid receptors and other prognostic factors in primary breast cancer. , 1988, Seminars in oncology.
[13] J. Robertson,et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. J. van de Vijver,et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.
[15] J. Robertson,et al. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. , 2000, European journal of cancer.
[16] W. Carney,et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Nicosia,et al. MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. , 2000, Molecular endocrinology.
[18] S. Martino,et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[20] M. Dowsett,et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] D. Berry,et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G Konecny,et al. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. , 2000, Cancer treatment and research.
[23] J. Foekens,et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. , 1995, Gene.
[24] A. Bianco,et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.